On this page
What Canada is doing
Canada is mobilizing industry and providing support for research, market approval, manufacturing and access to medical supplies. We're working proactively with companies that are developing new and innovative testing technologies. We're also engaging with international regulators to share knowledge about new developments related to testing.
Increasing testing options
Health Canada reviews testing devices to assess their safety, effectiveness and quality before they're authorized for sale in Canada. For a test to be authorized by Health Canada, it must be submitted for review by the manufacturer. To date, Health Canada has authorized over 50 different COVID-19 tests. We also continue to expedite the review of COVID-19 tests, including new testing options.
Health Canada is currently prioritizing the review of:
- tests that can be used at point-of-care to provide rapid diagnostic or monitoring results, including antigen tests
- saliva tests (tests that use spit as the sample instead of a sample from the nose or throat)
Health Canada has received a number of antigen test applications that are under priority review. Antigen tests detect specific proteins on the surface of the virus and provide rapid results.
A small number of saliva tests have been submitted to Health Canada and are under priority review. Health Canada hasn't authorized any tests for use with saliva at this time.
Health Canada will expedite the review of any new testing technologies submitted by manufacturers, including at-home test kits (also known as "self-testing"). For at-home test kits, the manufacturer must provide data to show the test is safe and effective for Canadians to use without health care professional supervision.
In all cases, companies must provide evidence that the test is accurate and reliable before Health Canada will authorize it. Health Canada has provided guidance to manufacturers on the authorization requirements for different types of tests such as antibody tests and antigen tests.
Securing rapid tests
Public Services and Procurement Canada has purchased rapid tests on behalf of and at the direction of the Public Health Agency of Canada. This purchase ensures that the federal government can increase testing capacity with authorized, proven and effective technologies. Explore COVID-19 rapid test purchase agreements.
Rapid tests distributed in Canada
The Government of Canada has purchased millions of rapid tests to distribute across the country and add an extra layer of defence against the spread of the virus. Find out about our rapid test agreements and types of tests we have purchased.
The tables below show the number of COVID-19 rapid tests that have been shipped in provinces and territories as of January 14, 2022 (deployment and usage data as of December 10, 2021). The data for “tests deployed” show the quantities of rapid tests that have been distributed to their final point-of-care setting where they will be administered to patients. The data for “tests used” depict how many of those rapid tests have been administered.
There is a delay in the reporting on the deployment of rapid tests. This is due to the time when tests are:
- shipped and delivered to provinces and territories
- redistributed throughout each jurisdiction
The numbers listed are updated regularly.
Canada
Distribution of tests in Canada
| Product name |
Tests shipped |
Tests shipped to PTs |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
6,611,544 |
5,642,272 |
2,415,804 |
1,127,684 |
| Abbott Panbio |
67,492,900 |
58,624,835 |
50,572,943 |
12,893,240 |
| BD Veritor |
12,256,290 |
10,492,710 |
9,442,593 |
1,126,113 |
| Quidel Sofia |
850,000 |
73,200 |
2,844 |
0 |
| BTNX |
58,073,200 |
57,954,460 |
5,765,475 |
150,640 |
| Roche |
1,750,000 |
559,925 |
0 |
0 |
| Quidel QuickVue |
9,238,275 |
2,002,450 |
287,375 |
3,906 |
| Lucira |
174,250 |
24,402 |
2,400 |
533 |
| Switch Health |
2,571,200 |
2,559,200 |
- |
- |
| Artron |
1,458,730 |
1,208,730 |
- |
- |
| Trimedic |
3,372,840 |
3,372,840 |
- |
- |
| CanAm |
1,663,700 |
0 |
- |
- |
| Total |
165,512,929 |
142,515,024 |
68,489,434 |
15,302,116 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Newfoundland and Labrador
Distribution of tests for Newfoundland and Labrador
| Product name |
Testrs shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
91,432 |
86,208 |
10,571 |
| Abbott Panbio |
305,000 |
304,375 |
15,258 |
| BD Veritor |
0 |
0 |
0 |
| BTNX |
250,020 |
0 |
0 |
| Roche |
0 |
0 |
0 |
| Quidel QuickVue |
805,475 |
0 |
0 |
| Lucira |
0 |
0 |
0 |
| Total |
1,451,927 |
390,583 |
25,829 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Prince Edward Island
Distribution of tests for Prince Edward Island
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
620,208 |
no information provided |
296,337 |
| Abbott Panbio |
196,000 |
50,800 |
50,800 |
| BD Veritor |
0 |
0 |
0 |
| BTNX |
200,000 |
63,260 |
18,000 |
| Roche |
0 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
5,000 |
0 |
0 |
| Switch Health |
160,000 |
- |
- |
| Total |
1,181,208 |
114,060 |
365,137 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Nova Scotia
Distribution of tests for Nova Scotia
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
106,512 |
1,491 |
1,491 |
| Abbott Panbio |
5,631,625 |
1,510,248 |
884,874 |
| BD Veritor |
920,520 |
508,452 |
121,452 |
| BTNX |
2,919,440 |
132,000 |
132,000 |
| Roche |
0 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
15,000 |
0 |
0 |
| Switch Health |
395,200 |
- |
- |
| Total |
9,988,297 |
2,152,191 |
1,139,817 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
New Brunswick
Distribution of tests for New Brunswick
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
111,040 |
13,268 |
1,126 |
| Abbott Panbio |
4,251,200 |
1,445,705 |
324,778 |
| BD Veritor |
0 |
0 |
0 |
| BTNX |
4,500,000 |
1,991,455 |
0 |
| Roche |
0 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
0 |
0 |
0 |
| Total |
8,862,240 |
3,450,428 |
325,904 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Quebec
Distribution of tests for Quebec
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
1,522,648 |
935,616 |
482,467 |
| Abbott Panbio |
8,463,750 |
5,657,619 |
28,636 |
| BD Veritor |
1,161,420 |
894,840 |
41,000 |
| BTNX |
19,729,280 |
0 |
0 |
| Roche |
0 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
1,802 |
0 |
0 |
| Total |
30,878,900 |
7,488,075 |
552,103 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Ontario
Distribution of tests for Ontario
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
1,338,432 |
549,975 |
108,329 |
| Abbott Panbio |
20,148,263 |
28,375,765 |
9,206,370 |
| BD Veritor |
4,364,220 |
3,867,805 |
366,930 |
| Quidel Sofia |
73,200 |
2,844 |
0 |
| BTNX |
11,324,940 |
1,252,060 |
0 |
| Roche |
0 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
0 |
0 |
0 |
| Switch Health |
1,872,000 |
no information provided |
no information reported |
| Artron |
457,820 |
- |
- |
| Trimedic |
3,372,840 |
- |
- |
| Total |
42,951,715 |
34,048,449 |
9,681,629 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used and may also include tests purchased by the province.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date and may also include tests purchased by the province.
Return to footnote ** referrer
|
Manitoba
Distribution of tests for Manitoba
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
176,448 |
21,024 |
no information provided |
| Abbott Panbio |
3,081,000 |
407,475 |
no information provided |
| BD Veritor |
995,250 |
11,520 |
no information provided |
| BTNX |
260,280 |
0 |
no information provided |
| Roche |
300,325 |
0 |
no information provided |
| Quidel QuickVue |
1,196,975 |
0 |
no information provided |
| Lucira |
0 |
0 |
no information provided |
| Switch Health |
132,000 |
no information provided |
no information provided |
| Total |
6,142,278 |
440,019 |
no information provided |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Saskatchewan
Distribution of tests for Saskatchewan
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
348,416 |
235,848 |
no information provided |
| Abbott Panbio |
6,224,775 |
3,510,575 |
no information provided |
| BD Veritor |
1,642,500 |
1,479,150 |
no information provided |
| BTNX |
8,180,870 |
2,287,675 |
no information provided |
| Roche |
0 |
0 |
no information provided |
| Quidel QuickVue |
0 |
0 |
no information provided |
| Lucira |
0 |
0 |
no information provided |
| Total |
16,396,561 |
7,513,248 |
no information provided |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
Data verification ongoing.
Return to footnote ** referrer
|
Alberta
Distribution of tests for Alberta
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
537,912 |
274,702 |
160,841 |
| Abbott Panbio |
6,694,772 |
4,325,034 |
1,247,082 |
| BD Veritor |
1,018,920 |
1,465,856 |
403,350 |
| BTNX |
10,542,470 |
39,025 |
640 |
| Roche |
30,000 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
2,600 |
2,400 |
533 |
| Total |
18,826,624 |
6,107,017 |
1,812,446 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
British Columbia
Distribution of tests for British Columbia
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
644,760 |
88,488 |
27,553 |
| Abbott Panbio |
3,370,900 |
1,091,400 |
237,632 |
| BD Veritor |
389,880 |
81,210 |
60,834 |
| BTNX |
0 |
0 |
0 |
| Roche |
0 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
0 |
0 |
0 |
| Artron |
750,910 |
- |
- |
| Total |
5,156,450 |
1,261,098 |
326,019 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Yukon
Distribution of tests for Yukon
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
23,648 |
no information provided |
no information provided |
| Abbott Panbio |
30,000 |
no information provided |
no information provided |
| BD Veritor |
0 |
0 |
0 |
| BTNX |
0 |
0 |
0 |
| Roche
| 229,600 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
0 |
0 |
0 |
| Total |
283,248 |
0 |
0 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Northwest Territories
Distribution of tests for Northwest Territories
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
93,480 |
40,656 |
20,040 |
| Abbott Panbio |
168,800 |
8,817 |
350 |
| BD Veritor |
0 |
0 |
0 |
| BTNX |
47,160 |
0 |
0 |
| Roche |
0 |
0 |
0 |
| Quidel QuickVue |
0 |
0 |
0 |
| Lucira |
0 |
0 |
0 |
| Total |
309,440 |
49,473 |
20,390 |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Nunavut
Distribution of tests for Nunavut
| Product name |
Tests shipped |
Tests deployedFootnote * |
Tests used (as reported)Footnote ** |
| Abbott ID Now |
27,336 |
5,424 |
no information provided |
| Abbott Panbio |
58,800 |
14,400 |
no information provided |
| BD Veritor |
0 |
0 |
no information provided |
| BTNX |
0 |
0 |
no information provided |
| Roche |
0 |
0 |
no information provided |
| Quidel QuickVue |
0 |
0 |
no information provided |
| Lucira |
0 |
0 |
no information provided |
| Total |
86,136 |
19,824 |
no information provided |
- Footnote *
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote * referrer
- Footnote **
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote ** referrer
|
Federal allocation
Distribution of tests for Federal OperationsFootnote *
| Product name |
Tests shippedFootnote ** |
Tests deployedFootnote *** |
Tests used (as reported)Footnote **** |
| Abbott ID Now |
280,136 |
280,136 |
19,909 |
| Abbott Panbio |
434,350 |
434,350 |
136,228 |
| BD Veritor |
11,600 |
11,600 |
363 |
| Quidel Sofia |
8,400 |
8,400 |
2,957 |
| Lucira |
1,034 |
1,034 |
0 |
| Quidel QuickVue |
325,000 |
325,000 |
82,771 |
| GeneXpert |
89,950 |
89,950 |
- |
| Total |
876,379 |
876,379 |
242,228 |
- Footnote *
-
The federal operations numbers include tests distributed to federal government departments such as: Department of National Defence (DND), Correctional Services Canada (CSC), the Public Health Agency of Canada (PHAC), as well as Northern, remote and Indigenous communities.
Return to footnote * referrer
- Footnote **
-
The tests shipped and deployed information includes data as of January 14, 2022. Usage data is current as of December 10, 2021.
Return to footnote ** referrer
- Footnote ***
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote *** referrer
- Footnote ****
-
The tests used information shows data that has been reported to Health Canada to date.
Return to footnote **** referrer
|
Direct to organizations for workplace screeningFootnote *
| Product name |
Tests available |
Tests deployedFootnote ** |
Tests used (as reported)Footnote *** |
| Abbott ID Now |
0 |
0 |
0 |
| Abbott Panbio |
4,578,625 |
3,572,405 |
916,263 |
| BD Veritor |
1,133,760 |
1,133,760 |
195,568 |
| BTNX |
- |
- |
1,418 |
| Quidel Sofia |
0 |
0 |
0 |
| Quidel QuickVue |
287,375 |
287,375 |
42,227 |
| Total |
5,999,760 |
4,993,540 |
1,155,476 |
- Footnote *
-
Federal distribution numbers include tests shipped to businesses, non-profit organizations, crown corporations, and distribution partners such as pharmacies and the Canadian Red Cross.
Return to footnote * referrer
- Footnote **
-
The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.
Return to footnote ** referrer
- Footnote ***
-
The tests used information shows data that has been reported to Health Canada as of January 14, 2022. Tests available and deployed data is current as of December 10, 2021.
Return to footnote *** referrer
|
Supporting provincial and territorial COVID-19 testing capacity
The federal government is providing $4.28 billion to the provinces and territories. This money is to help them conduct testing, perform contact tracing and share public health data that will help fight the pandemic. The goal is to ensure they have the capacity to test up to 200,000 people each day, nationwide.
Canada is also providing funding and support to improve and modernize data management across Canada. This support is to help all levels of government coordinate their efforts to contain the virus.
The table below shows the current capacity for each province and territory compared to the capacity target agreed to under the Safe Restart Agreement.
The national capacity target of about 200,000 tests each day is based on modelling. This modelling exercise indicates this capacity is enough to meet the expected demand for testing.
Provincial and territorial COVID-19 testing capacity
Testing capacity reported as of November 30, 2021.
Please consult the Coronavirus disease 2019 (COVID-19): Epidemiology update for daily and weekly updates on the average number of people tested.
In circumstances where capacity was not reported, the previous week's capacity was indicated (see *).
Newfoundland and Labrador: Target 2,500 - 3,000
COVID-19 testing capacity for Newfoundland and Labrador (Target 2,500 - 3,000Footnote***)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
1,450 |
| 2020-09-10 |
1,450 |
| 2020-09-17 |
1,450 |
| 2020-09-24 |
1,450 |
| 2020-10-01 |
1,450 |
| 2020-10-08 |
1,450 |
| 2020-10-15 |
1,450 |
| 2020-10-22 |
1,450 |
| 2020-10-29 |
1,450 |
| 2020-11-03 |
1,450 |
| 2020-11-10 |
1,450 |
| 2020-11-17 |
1,450 |
| 2020-11-24 |
1,450 |
| 2020-12-01 |
1,450 |
| 2020-12-08 |
1,450 |
| 2020-12-15 |
1,450 |
| 2020-12-22 |
1,450 |
| 2020-12-29 |
1,450 |
| 2021-01-05 |
1,450 |
| 2021-01-12 |
1,450 |
| 2021-01-19 |
1,450 |
| 2021-01-26 |
1,450 |
| 2021-02-02 |
1,450 |
| 2021-02-09 |
1,700 |
| 2021-02-16 |
1,700Footnote * |
| 2021-02-23 |
1,700 |
| 2021-03-02 |
1,700 |
| 2021-03-09 |
1,700 |
| 2021-03-16 |
1,700 |
| 2021-03-23 |
2,100 |
| 2021-03-29 |
2,100 |
| 2021-04-06 |
2,100 |
| 2021-04-12 |
2,500 |
| 2021-04-19 |
2,500 |
| 2021-04-26 |
2,500 |
| 2021-05-03 |
2,700 |
| 2021-05-10 |
2,700 |
| 2021-05-17 |
2,700 |
| 2021-05-24 |
2,700 |
| 2021-05-31 |
2,700 |
| 2021-06-30 |
2,700 |
| 2021-07-31 |
2,700 |
| 2021-08-31 |
2,700 |
| 2021-09-30 |
2,700 |
| 2021-10-31 |
2,700 |
| 2021-11-30 |
2,700 |
|
Prince Edward Island: Target 835
COVID-19 testing capacity for Prince Edward Island (Target 835)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
350 |
| 2020-09-10 |
430 |
| 2020-09-17 |
350 |
| 2020-09-24 |
350 |
| 2020-10-01 |
400 |
| 2020-10-08 |
400 |
| 2020-10-15 |
400 (800Footnote**) |
| 2020-10-22 |
400 (800Footnote**) |
| 2020-10-29 |
400 (800Footnote**) |
| 2020-11-03 |
400 (800Footnote**) |
| 2020-11-10 |
400 (800Footnote**) |
| 2020-11-17 |
400 (800Footnote**) |
| 2020-11-24 |
400 (800Footnote**) |
| 2020-12-01 |
400 (800Footnote**) |
| 2020-12-08 |
400Footnote* (800Footnote**) |
| 2020-12-15 |
400 (800Footnote**) |
| 2020-12-22 |
400 |
| 2020-12-29 |
400 |
| 2021-01-05 |
600 |
| 2021-01-12 |
600 |
| 2021-01-19 |
600 |
| 2021-01-26 |
600 |
| 2021-02-02 |
700 |
| 2021-02-09 |
850 |
| 2021-02-16 |
850 |
| 2021-02-23 |
850 |
| 2021-03-02 |
850 |
| 2021-03-09 |
850 |
| 2021-03-16 |
850 |
| 2021-03-23 |
850 |
| 2021-03-29 |
850 |
| 2021-04-06 |
850 |
| 2021-04-12 |
850 |
| 2021-04-19 |
850 |
| 2021-04-26 |
850 |
| 2021-05-03 |
850 |
| 2021-05-10 |
850 |
| 2021-05-17 |
850 |
| 2021-05-24 |
850 |
| 2021-05-31 |
850 |
| 2021-06-30 |
850 |
| 2021-07-31 |
850 |
| 2021-08-31 |
850 |
| 2021-09-30 |
850 |
| 2021-10-31 |
850 |
| 2021-11-30 |
850 |
|
Nova Scotia: Target 2,500
COVID-19 testing capacity for Nova Scotia (Target 2,500)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
1,500 |
| 2020-09-10 |
1,500 |
| 2020-09-17 |
1,500 |
| 2020-09-24 |
1,500 |
| 2020-10-01 |
1,500 |
| 2020-10-08 |
1,500 |
| 2020-10-15 |
1,500 |
| 2020-10-22 |
1,500 |
| 2020-10-29 |
1,500 |
| 2020-11-03 |
1,500 |
| 2020-11-10 |
1,500 |
| 2020-11-17 |
1,500 |
| 2020-11-24 |
2,500 |
| 2020-12-01 |
2,500 |
| 2020-12-08 |
2,500 |
| 2020-12-15 |
2,500 |
| 2020-12-22 |
2,500 |
| 2020-12-29 |
2,500 |
| 2021-01-05 |
2,500 |
| 2021-01-12 |
2,500 |
| 2021-01-19 |
2,500 |
| 2021-01-26 |
2,500 |
| 2021-02-02 |
2,500 |
| 2021-02-09 |
2,500 |
| 2021-02-16 |
2,500 |
| 2021-02-23 |
2,500 |
| 2021-03-02 |
2,500 |
| 2021-03-09 |
2,500 |
| 2021-03-16 |
2,500 |
| 2021-03-23 |
2,500 |
| 2021-03-29 |
2,500 |
| 2021-04-06 |
2,500 |
| 2021-04-12 |
2,500 |
| 2021-04-19 |
2,500 |
| 2021-04-26 |
2,500 |
| 2021-05-03 |
10,000 |
| 2021-05-10 |
10,000 |
| 2021-05-17 |
10,000 |
| 2021-05-24 |
10,000 |
| 2021-05-31 |
10,000 |
| 2021-06-30 |
10,000 |
| 2021-07-31 |
10,000 |
| 2021-08-31 |
10,000 |
| 2021-09-30 |
10,000 |
| 2021-10-31 |
10,000 |
| 2021-11-30 |
10,000 |
New Brunswick: Target 2,500 - 3,000
COVID-19 testing capacity for New Brunswick (Target 2,500 - 3,000)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
1,500 |
| 2020-09-10 |
1,500 |
| 2020-09-17 |
1,500 |
| 2020-09-24 |
1,500 |
| 2020-10-01 |
1,500 |
| 2020-10-08 |
1,500 |
| 2020-10-15 |
1,500 |
| 2020-10-22 |
1,500 |
| 2020-10-29 |
2,000 |
| 2020-11-03 |
2,000 |
| 2020-11-10 |
2,000 |
| 2020-11-17 |
2,000 |
| 2020-11-24 |
2,000Footnote* |
| 2020-12-01 |
2,000 |
| 2020-12-08 |
2,000Footnote* |
| 2020-12-15 |
2,500 |
| 2020-12-22 |
2,500 |
| 2020-12-29 |
2,500 |
| 2021-01-05 |
2,500 |
| 2021-01-12 |
2,000 |
| 2021-01-19 |
2,000 |
| 2021-01-26 |
2,000 |
| 2021-02-02 |
2,000 |
| 2021-02-09 |
3,000 |
| 2021-02-16 |
3,000 |
| 2021-02-23 |
3,000 |
| 2021-03-02 |
3,000 |
| 2021-03-09 |
3,000 |
| 2021-03-16 |
3,000 |
| 2021-03-23 |
3,000 |
| 2021-03-29 |
3,000 |
| 2021-04-06 |
3,000 |
| 2021-04-12 |
3,000 |
| 2021-04-19 |
3,000 |
| 2021-04-26 |
3,000 |
| 2021-05-03 |
3,000 |
| 2021-05-10 |
3,000 |
| 2021-05-17 |
3,000 |
| 2021-05-24 |
3,000 |
| 2021-05-31 |
3,000 |
| 2021-06-30 |
3,000 |
| 2021-07-31 |
3,000 |
| 2021-08-31 |
3,000 |
| 2021-09-30 |
3,000 |
| 2021-10-31 |
3,000 |
| 2021-11-30 |
3,000 |
Quebec: Target 35,000
COVID-19 testing capacity for Quebec (Target 35,000)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
20,000 |
| 2020-09-10 |
20,000 |
| 2020-09-17 |
20,000 |
| 2020-09-24 |
20,000 |
| 2020-10-01 |
20,000 |
| 2020-10-08 |
20,000 |
| 2020-10-15 |
20,000 |
| 2020-10-22 |
20,000 |
| 2020-10-29 |
20,000 |
| 2020-11-03 |
20,000 |
| 2020-11-10 |
20,000 |
| 2020-11-17 |
20,000 |
| 2020-11-24 |
20,000 |
| 2020-12-01 |
20,000 |
| 2020-12-08 |
35,199 |
| 2020-12-15 |
37,142 |
| 2020-12-22 |
38,846 |
| 2020-12-29 |
40,196 |
| 2021-01-05 |
37,972 |
| 2021-01-12 |
39,127 |
| 2021-01-19 |
36,929 |
| 2021-01-26 |
40,084 |
| 2021-02-02 |
40,977 |
| 2021-02-09 |
42,386 |
| 2021-02-16 |
39,497 |
| 2021-02-23 |
43,987 |
| 2021-03-02 |
41,386 |
| 2021-03-09 |
42,758 |
| 2021-03-16 |
42,427 |
| 2021-03-23 |
43,382 |
| 2021-03-29 |
44,037 |
| 2021-04-06 |
46,392 |
| 2021-04-12 |
48,221 |
| 2021-04-19 |
47,959 |
| 2021-04-26 |
47,659 |
| 2021-05-03 |
47,771 |
| 2021-05-10 |
48,098 |
| 2021-05-17 |
48,471 |
| 2021-05-24 |
46,104 |
| 2021-05-31 |
46,338 |
| 2021-06-30 |
46,048 |
| 2021-07-31 |
46,048 |
| 2021-08-31 |
47,653 |
| 2021-09-30 |
47,653 |
| 2021-10-31 |
46,915 |
| 2021-11-30 |
46,915 |
Ontario: Target 78,000
COVID-19 testing capacity for Ontario (Target 78,000)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
35,108 |
| 2020-09-10 |
39,690 |
| 2020-09-17 |
42,434 |
| 2020-09-24 |
42,816 |
| 2020-10-01 |
42,942 |
| 2020-10-08 |
50,692 |
| 2020-10-15 |
51,397 |
| 2020-10-22 |
64,340 |
| 2020-10-29 |
67,094 |
| 2020-11-03 |
71,564 |
| 2020-11-10 |
78,964 |
| 2020-11-17 |
80,856 |
| 2020-11-24 |
81,630 |
| 2020-12-01 |
81,630 |
| 2020-12-08 |
74,008 |
| 2020-12-15 |
77,333 |
| 2020-12-22 |
77,333 |
| 2020-12-29 |
77,581 |
| 2021-01-05 |
79,821 |
| 2021-01-12 |
120,608 |
| 2021-01-19 |
120,608 |
| 2021-01-26 |
120,608 |
| 2021-02-02 |
116,000 |
| 2021-02-09 |
116,000 |
| 2021-02-16 |
116,000 |
| 2021-02-23 |
116,000 |
| 2021-03-02 |
116,000 |
| 2021-03-09 |
117,800 |
| 2021-03-16 |
118,400 |
| 2021-03-23 |
118,400 |
| 2021-03-29 |
118,400 |
| 2021-04-06 |
120,200 |
| 2021-04-12 |
120,200 |
| 2021-04-19 |
120,200 |
| 2021-04-26 |
120,200 |
| 2021-05-03 |
120,200 |
| 2021-05-10 |
124,700 |
| 2021-05-17 |
124,700 |
| 2021-05-24 |
124,700 |
| 2021-05-31 |
124,700 |
| 2021-06-30 |
124,700 |
| 2021-07-31 |
124,700 |
| 2021-08-31 |
124,700 |
| 2021-09-30 |
124,700 |
| 2021-10-31 |
124,700 |
| 2021-11-30 |
124,700 |
Manitoba: Target 3,000
COVID-19 testing capacity for Manitoba (Target 3,000)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
3,000 |
| 2020-09-10 |
3,000 |
| 2020-09-17 |
3,000 |
| 2020-09-24 |
3,000 |
| 2020-10-01 |
3,000 |
| 2020-10-08 |
3,000 |
| 2020-10-15 |
3,000 |
| 2020-10-22 |
3,000 |
| 2020-10-29 |
3,000 |
| 2020-11-03 |
3,000 |
| 2020-11-10 |
3,000 |
| 2020-11-17 |
3,000 |
| 2020-11-24 |
3,000Footnote* |
| 2020-12-01 |
2,841 |
| 2020-12-08 |
2,841Footnote* |
| 2020-12-15 |
2,841Footnote* |
| 2020-12-22 |
3,500 |
| 2020-12-29 |
3,500 |
| 2021-01-05 |
3,500 |
| 2021-01-12 |
3,500 |
| 2021-01-19 |
3,500 |
| 2021-01-26 |
3,500 |
| 2021-02-02 |
3,500 |
| 2021-02-09 |
3,500Footnote* |
| 2021-02-16 |
3,500 |
| 2021-02-23 |
3,500 |
| 2021-03-02 |
3,500 |
| 2021-03-09 |
3,500Footnote* |
| 2021-03-16 |
3,500 |
| 2021-03-23Footnote* |
3,500 |
| 2021-03-29 |
3,500 |
| 2021-04-06 |
3,500Footnote* |
| 2021-04-12 |
3,500Footnote* |
| 2021-04-19 |
3,500Footnote* |
| 2021-04-26 |
3,500Footnote* |
| 2021-05-03 |
3,500Footnote* |
| 2021-05-10 |
3,500Footnote* |
| 2021-05-17 |
3,500Footnote* |
| 2021-05-24 |
3,500Footnote* |
| 2021-05-31 |
3,500Footnote* |
| 2021-06-30 |
3,500Footnote* |
| 2021-07-31 |
3,500Footnote* |
| 2021-08-31 |
4,000 |
| 2021-09-30 |
4,000 |
| 2021-10-31 |
4,000 |
| 2021-11-30 |
4,000 |
Saskatchewan: Target 4,000
COVID-19 testing capacity for Saskatchewan (Target 4,000)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
1,800 |
| 2020-09-10 |
1,800 |
| 2020-09-17 |
1,800 |
| 2020-09-24 |
1,800 |
| 2020-10-01 |
1,800 |
| 2020-10-08 |
1,800 |
| 2020-10-15 |
1,800 |
| 2020-10-22 |
1,800 |
| 2020-10-29 |
1,800 |
| 2020-11-03 |
1,800 |
| 2020-11-10 |
2,100 |
| 2020-11-17 |
2,700 |
| 2020-11-24 |
2,700 |
| 2020-12-01 |
3,330 |
| 2020-12-08 |
3,450 |
| 2020-12-15 |
3,450 |
| 2020-12-22 |
3,450 |
| 2020-12-29 |
3,450 |
| 2021-01-05 |
3,846 |
| 2021-01-12 |
3,846 |
| 2021-01-19 |
3,846 |
| 2021-01-26 |
3,846 |
| 2021-02-02 |
3,846 |
| 2021-02-09 |
3,846Footnote* |
| 2021-02-16 |
3,846Footnote* |
| 2021-02-23 |
3,846 |
| 2021-03-02 |
3,846 |
| 2021-03-09 |
3,846 |
| 2021-03-16 |
4,000 |
| 2021-03-23 |
4,500 |
| 2021-03-29 |
4,500 |
| 2021-04-06 |
4,500 |
| 2021-04-12 |
4,500 |
| 2021-04-19 |
4,500 |
| 2021-04-26 |
4,500 |
| 2021-05-03 |
4,500 |
| 2021-05-10 |
4,500 |
| 2021-05-17 |
4,500 |
| 2021-05-24 |
4,500 |
| 2021-05-31 |
4,500 |
| 2021-07-31 |
4,500 |
| 2021-08-31 |
4,500 |
| 2021-09-30 |
3,000 |
| 2021-10-31 |
3,000 |
| 2021-11-30 |
3,000 |
Alberta: Target 22,000
COVID-19 testing capacity for Alberta (Target 22,000)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
12,000 |
| 2020-09-10 |
12,000 |
| 2020-09-17 |
12,000 |
| 2020-09-24 |
12,000 |
| 2020-10-01 |
15,500 |
| 2020-10-08 |
22,000 |
| 2020-10-15 |
22,000 |
| 2020-10-22 |
22,000 |
| 2020-10-29 |
22,000 |
| 2020-11-03 |
22,000 |
| 2020-11-10 |
22,000 |
| 2020-11-17 |
22,000 |
| 2020-11-24 |
22,000 |
| 2020-12-01 |
22,000 |
| 2020-12-08 |
22,000Footnote* |
| 2020-12-15 |
22,000 |
| 2020-12-22 |
22,000 |
| 2020-12-29 |
22,000 |
| 2021-01-05 |
22,000 |
| 2021-01-12 |
22,000 |
| 2021-01-19 |
22,000 |
| 2021-01-26 |
22,000 |
| 2021-02-02 |
22,000 |
| 2021-02-09 |
22,000 |
| 2021-02-16 |
22,000 |
| 2021-02-23 |
22,000 |
| 2021-03-02 |
22,000 |
| 2021-03-09 |
22,000 |
| 2021-03-16 |
22,000 |
| 2021-03-23 |
22,000 |
| 2021-03-29 |
22,000 |
| 2021-04-06 |
22,000 |
| 2021-04-12 |
22,000 |
| 2021-04-19 |
22,000 |
| 2021-04-26 |
22,000 |
| 2021-05-03 |
22,000 |
| 2021-05-10 |
22,000 |
| 2021-05-17 |
22,000 |
| 2021-05-24 |
22,000 |
| 2021-05-31 |
22,000 |
| 2021-06-30 |
22,000 |
| 2021-07-31 |
22,000 |
| 2021-08-31 |
22,000 |
| 2021-09-30 |
22,000 |
| 2021-11-30 |
22,000 |
British Columbia: Target 20,000
COVID-19 testing capacity for British Columbia (Target 20,000)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
7,842 |
| 2020-09-10 |
8,581 |
| 2020-09-17 |
7,996 |
| 2020-09-24 |
9,633 |
| 2020-10-01 |
9,714 |
| 2020-10-08 |
10,506 |
| 2020-10-15 |
10,586 |
| 2020-10-22 |
12,840 |
| 2020-10-29 |
13,685 |
| 2020-11-03 |
17,033 |
| 2020-11-10 |
17,333 |
| 2020-11-17 |
18,733 |
| 2020-11-24 |
18,733 |
| 2020-12-01 |
18,733 |
| 2020-12-08 |
18,945 |
| 2020-12-15 |
18,945 |
| 2020-12-22 |
18,945 |
| 2020-12-29 |
18,945 |
| 2021-01-05 |
19,439 |
| 2021-01-12 |
19,439 |
| 2021-01-19 |
19,817 |
| 2021-01-26 |
19,817 |
| 2021-02-02 |
19,817 |
| 2021-02-09 |
19,817 |
| 2021-02-16 |
19,817 |
| 2021-02-23 |
20,617 |
| 2021-03-02 |
20,617 |
| 2021-03-09 |
20,617 |
| 2021-03-16 |
20,617 |
| 2021-03-23 |
21,332 |
| 2021-03-29 |
21,332 |
| 2021-04-06 |
19,932 |
| 2021-04-12 |
18,932 |
| 2021-04-19 |
20,132 |
| 2021-04-26 |
20,132 |
| 2021-05-03 |
20,132 |
| 2021-05-10 |
20,132 |
| 2021-05-17 |
20,132 |
| 2021-05-24 |
20,132 |
| 2021-05-31 |
20,132 |
| 2021-06-30 |
20,132 |
| 2021-07-31 |
20,132 |
| 2021-08-31 |
20,132 |
| 2021-09-30 |
19,628 |
| 2021-10-31 |
19,628 |
| 2021-11-30 |
19,628 |
Yukon: Target 160
COVID-19 testing capacity for Yukon (Target 160)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
n/a |
| 2020-09-10 |
n/a |
| 2020-09-17 |
n/a |
| 2020-09-24 |
n/a |
| 2020-10-01 |
150 |
| 2020-10-08 |
150 |
| 2020-10-15 |
150 |
| 2020-10-22 |
150 |
| 2020-10-29 |
150 |
| 2020-11-03 |
150 |
| 2020-11-10 |
150 |
| 2020-11-17 |
150 |
| 2020-11-24 |
150 |
| 2020-12-01 |
150Footnote* |
| 2020-12-08 |
150Footnote* |
| 2020-12-15 |
150 |
| 2020-12-22 |
150 |
| 2020-12-22 |
150 |
| 2020-12-29 |
150 |
| 2021-01-05 |
150 |
| 2021-01-12 |
150 |
| 2021-01-19 |
150 |
| 2021-01-26 |
150Footnote* |
| 2021-02-02 |
150Footnote* |
| 2021-02-09 |
150 |
| 2021-02-16 |
150Footnote* |
| 2021-02-23 |
150Footnote* |
| 2021-03-02 |
150 |
| 2021-03-09 |
150Footnote* |
| 2021-03-16 |
150Footnote* |
| 2021-03-23 |
150 |
| 2021-03-29 |
150 |
| 2021-04-06 |
150 |
| 2021-04-12 |
150 |
| 2021-04-19 |
150 |
| 2021-04-26 |
150 |
| 2021-05-03 |
150 |
| 2021-05-10 |
150 |
| 2021-05-17 |
150 |
| 2021-05-24 |
150 |
| 2021-05-31 |
150 |
| 2021-06-30 |
150 |
| 2021-07-31 |
150 |
| 2021-08-31 |
150 |
| 2021-09-30 |
150 |
| 2021-10-31 |
150 |
| 2021-11-30 |
150 |
Northwest Territories: Target 225
COVID-19 testing capacity for Northwest Territories (Target 225)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
n/a |
| 2020-09-10 |
n/a |
| 2020-09-17 |
n/a |
| 2020-09-24 |
n/a |
| 2020-10-01 |
48 |
| 2020-10-08 |
48 |
| 2020-10-15 |
48 |
| 2020-10-22 |
48 |
| 2020-10-29 |
75 |
| 2020-11-03 |
75 |
| 2020-11-10 |
75 |
| 2020-11-17 |
75 |
| 2020-11-24 |
75 |
| 2020-12-01 |
75Footnote* |
| 2020-12-08 |
75Footnote* |
| 2020-12-15 |
75Footnote* |
| 2020-12-22 |
75 |
| 2020-12-29 |
75 |
| 2021-01-05 |
75 |
| 2021-01-12 |
75 |
| 2021-01-19 |
75 |
| 2021-01-26 |
75* |
| 2021-02-02 |
110 |
| 2021-02-09 |
110 |
| 2021-02-16 |
110 |
| 2021-02-23 |
110 |
| 2021-03-02 |
110 |
| 2021-03-09 |
110 |
| 2021-03-16 |
110 |
| 2021-03-23 |
110 |
| 2021-03-29 |
110 |
| 2021-04-06 |
110 |
| 2021-04-12 |
100 |
| 2021-04-19 |
110 |
| 2021-04-26 |
110 |
| 2021-05-03 |
110 |
| 2021-05-10 |
110 |
| 2021-05-17 |
110 |
| 2021-05-24 |
110 |
| 2021-05-31 |
110 |
| 2021-06-30 |
110 |
| 2021-07-31 |
110 |
| 2021-08-31 |
110 |
| 2021-09-30 |
110 |
| 2021-10-31 |
110 |
| 2021-11-30 |
110 |
Nunavut: Target n/a
COVID-19 testing capacity for Nunavut (Target n/a)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
n/a |
| 2020-09-10 |
n/a |
| 2020-09-17 |
n/a |
| 2020-09-24 |
n/a |
| 2020-10-01 |
n/a |
| 2020-10-08 |
n/a |
| 2020-10-15 |
80 |
| 2020-10-22 |
80 |
| 2020-10-29 |
80 |
| 2020-11-03 |
100 |
| 2020-11-10 |
200 |
| 2020-11-17 |
200 |
| 2020-11-24 |
200 |
| 2020-12-01 |
200 |
| 2020-12-08 |
200 |
| 2020-12-15 |
250 |
| 2020-12-22 |
250 |
| 2020-12-29 |
250 |
| 2021-01-05 |
250 |
| 2021-01-12 |
250 |
| 2021-01-19 |
300 |
| 2021-01-26 |
300 |
| 2021-02-02 |
300 |
| 2021-02-09 |
300 |
| 2021-02-16 |
300 |
| 2021-02-23 |
300 |
| 2021-03-02 |
300 |
| 2021-03-09 |
300 |
| 2021-03-16 |
300 |
| 2021-03-23 |
300 |
| 2021-03-29 |
300 |
| 2021-04-06 |
300 |
| 2021-04-12 |
300 |
| 2021-04-19 |
300 |
| 2021-04-26 |
300 |
| 2021-05-03 |
300 |
| 2021-05-10 |
300 |
| 2021-05-17 |
300 |
| 2021-05-24 |
300 |
| 2021-05-31 |
300 |
| 2021-06-30 |
300 |
| 2021-07-31 |
300 |
| 2021-08-31 |
300 |
| 2021-09-30 |
300 |
| 2021-10-31 |
300 |
| 2021-11-30 |
300 |
Canada: Target 170,720 - 171,220
COVID-19 testing capacity for Canada (Target 170,720 - 171,220)
| Date |
Projected daily maximum testing capacity |
| 2020-09-03 |
84,550 |
| 2020-09-10 |
89,951 |
| 2020-09-17 |
92,030 |
| 2020-09-24 |
94,049 |
| 2020-10-01 |
82,504 |
| 2020-10-08 |
113,046 |
| 2020-10-15 |
113,911 |
| 2020-10-22 |
128,838 |
| 2020-10-29 |
132,234 |
| 2020-11-03 |
141,072 |
| 2020-11-10 |
149,172 |
| 2020-11-17 |
153,064 |
| 2020-11-24 |
154,838 |
| 2020-12-01 |
155,309 |
| 2020-12-08 |
163,218 |
| 2020-12-15 |
169,036 |
| 2020-12-22 |
171,399 |
| 2020-12-29 |
172,997 |
| 2021-01-05 |
174,103 |
| 2021-01-12 |
215,545 |
| 2021-01-19 |
213,775 |
| 2021-01-26 |
216,930 |
| 2021-02-02 |
213,350 |
| 2021-02-09 |
216,159 |
| 2021-02-16 |
213,270 |
| 2021-02-23 |
218,560 |
| 2021-03-02 |
215,959 |
| 2021-03-09 |
219,131 |
| 2021-03-16 |
219,599 |
| 2021-03-23 |
222,124 |
| 2021-03-29 |
222,779 |
| 2021-04-06 |
225,534 |
| 2021-04-12 |
226,763 |
| 2021-04-19 |
227,701 |
| 2021-04-26 |
227,401 |
| 2021-05-03 |
235,213 |
| 2021-05-10 |
240,040 |
| 2021-05-17 |
240,413 |
| 2021-05-24 |
238,046 |
| 2021-05-31 |
238,280 |
| 2021-06-30 |
237,990 |
| 2021-07-31 |
237,990 |
| 2021-08-31 |
240,095 |
| 2021-09-30 |
238,091 |
| 2021-10-31 |
237,353 |
| 2021-11-30 |
237,353 |
Related links
